Skip to content

Contact +44 (0) 20 7060 7474 email us

Medical Devices

China in Vitro Diagnostics Investment Opportunities

Analysis and Forecasts to 2015

Publication Date April 2009
Publisher Global Markets Direct
Product Type Report
Pages 152
ISBN Number not applicable
Product Code GMD02544

Price

£1,650.00
approximately: $2,498 | €1,842

pdf

Buy Now

Order above formats by FAX

Order by Fax

Summary

This report is an essential source for in-depth information and data relating to the China In vitro diagnostic dvices market. It also offers detailed and comprehensive coverage of market revenue, distribution and company share information; and latest news, financial deals and pipeline products information of each of the key sub-segments of the in vitro diagnostics market in China

Scope

  • The report provides in vitro diagnostics information broken down into detailed categories and segments in China.
  • Total revenues, end users
  • Market shares of all the key competitors.
  • Key pipeline products that are set to shape the market, broken down by sector.
  • Information on the top medical equipment companies in the sector in the country covering business description, strategic analysis.
  • Healthcare structure, regulatory environment, approval process, pricing trends and reimbursement.
  • Product and brand updates, strategy changes, R&D projects, corporate expansions and contractions and regulatory changes.
  • Key mergers and acquisitions, partnerships, private equity investments and IPOs.
  • Customer, hospitals and physicians data.

Reasons to buy

  • Gain a strong understanding of the in vitro diagnostics devices market in China.
  • Evaluate and compare the attractiveness of the market in the country.
  • Identify growth segments and opportunities in each industry sector within the country.
  • Evaluate the pipeline of key products that will change the sector, and identify threats and opportunities before the products are launched in the country.
  • Analyze the competitiveness of the market in the country and identify hotspots.
  • Develop strategies based on the latest product, brand, expansion and research and development news in the country.
  • Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the market in the country.
  • Identify and analyze the strengths and weaknesses of the industry incumbents in the country.

Contents

  • 1 List of Tables
  • 1.2 List of Figures
  • 2 Introduction
    • 2.1 What Is This Report About?
  • 3 Definitions of Markets Covered in This Report
  • 4 In Vitro Diagnostics
    • 4.1 Clinical Chemistry Test Reagents
      • 4.1.1 Laboratory Reagents
      • 4.1.2 Clinical Chemistry Calibrators and Controls
      • 4.1.3 Clinical Chemistry Rapid Tests
    • 4.2 Immunochemistry Test Reagents
      • 4.2.1 Disease Specific Markers
        • 4.2.1.1 Tumor Markers
        • 4.2.1.2 Cardiac Markers
      • 4.2.2 Disease Specific Test Reagents
        • 4.2.2.1 Auto-Immune Disease
        • 4.2.2.2 Rheumatoid Disease
        • 4.2.2.3 Anemia/ Vitamins
        • 4.2.2.4 Allergy
      • 4.2.3 Drug Related Testing Reagents
        • 4.2.3.1 Therapeutic Drugs
        • 4.2.3.2 Drug of Abuse and Toxicology
      • 4.2.4 Hormone Related Testing Reagents
        • 4.2.4.1 Specific Proteins
        • 4.2.4.2 Fertility and Pregnancy
        • 4.2.4.3 Individual/Specified hormones
        • 4.2.4.4 Specific Organ Function
      • 4.2.5 Immunochemistry Calibrators and Controls
      • 4.2.6 Immunochemistry Rapid Tests
    • 4.3 Blood Test Reagents
      • 4.3.1 Hematology Test Reagents
        • 4.3.1.1 Hematology
        • 4.3.1.2 Immunohaematology
        • 4.3.1.3 Hematology Calibrators and Controls
        • 4.3.1.4 Immunohaematology Controls
      • 4.3.2 Hemostasis Test Reagents
        • 4.3.2.1 Hemostasis
        • 4.3.2.2 Hemostasis Calibrators and Controls
        • 4.3.2.3 Hemostasis Rapid Tests
      • 4.3.3 Tissue Typing Reagents
      • 4.3.4 Monoclonal Antibodies
      • 4.3.5 Cytokines and Immunomodulators
      • 4.3.6 Histology and Cytology Reagents
    • 4.4 Microbiology Test Reagents
      • 4.4.1 Bacteriology Test Reagents
        • 4.4.1.1 Bacteriology Culture
        • 4.4.1.2 Blood Culture
        • 4.4.1.3 Bacteriology Identification and Susceptibility
      • 4.4.2 Microbiology Calibrators and Controls
      • 4.4.3 Microbiology Rapid Tests
    • 4.5 Infectious Immunology Test Reagents
      • 4.5.1 Bacteriology
      • 4.5.2 Virology
        • 4.5.2.1 Hepatitis Viruses
        • 4.5.2.2 Retroviruses
      • 4.5.3 Parasitology
      • 4.5.4 Infectious Immunology Calibrators and Controls
      • 4.5.5 Infectious Immunology Rapid Tests
    • 4.6 Genetic Test Reagents
    • 4.7 Self Testing
    • 4.8 Instruments
  • 5 Healthcare Sector Review
    • 5.1 Healthcare Expenditure
    • 5.2 Healthcare Infrastructure
      • 5.2.1 Healthcare Personnel Data
      • 5.2.2 Healthcare Facilities Data
    • 5.3 Healthcare Policy
  • 6 Regulation System
    • 6.1 Medical Equipment Approval Process
      • 6.1.1 Classification
      • 6.1.2 Registration and Conformity assessment
      • 6.1.3 China Compulsory Certificate (CCC Mark)
      • 6.1.4 Labeling and Packaging
      • 6.1.5 Registration Fee
      • 6.1.6 Registration Period
    • 6.2 Post Market Surveillance (PMS)
  • 7 Pricing and Reimbursement
  • 8 Distribution Structure
  • 9 In Vitro Diagnostics In China
    • 9.1 In Vitro Diagnostics Cross Country Comparison, Revenue ($ mn), 2000-2015
    • 9.2 In Vitro Diagnostics, China, Overall Revenue ($ mn), 2000-2015
    • 9.3 In Vitro Diagnostics, China, Company Share (2006-2007)
  • 10 Blood Test Reagents In China
    • 10.1 Blood Test Reagents Overall Revenue (2000-2015)
      • 10.1.1 Haematology Test Reagents Revenue (2000-2015)
      • 10.1.2 Hemostasis Test Reagents Revenue (2000-2015)
    • 10.2 Blood Test Reagents Distribution Share (2007-2008)
    • 10.3 Blood Test Reagents, China, Company Share (2006-2007)
  • 11 Clinical Chemistry Test Reagents In China
    • 11.1 Clinical Chemistry Test Reagents Overall Revenue (2000-2015)
    • 11.2 Clinical Chemistry Test Reagents Distribution Share (2007-2008)
    • 11.3 Clinical Chemistry Test Reagents, China, Company Share (2006-2007)
  • 12 Genetic Test Reagents In China
    • 12.1 Genetic Test Reagents Overall Revenue (2000-2015)
    • 12.2 Genetic Test Reagents Distribution Share (2007-2008)
    • 12.3 Genetic Test Reagents, China, Company Share (2006-2007)
  • 13 Immunochemistry Test Reagents In China
    • 13.1 Immunochemistry Test Reagents Overall Revenue (2000-2015)
      • 13.1.1 Disease Specific Markers Revenue (2000-2015)
      • 13.1.2 Disease Specific Test Reagents Revenue (2000-2015)
      • 13.1.3 Drug Related Testing Reagents Revenue (2000-2015)
      • 13.1.4 Hormone Related Testing Reagents Revenue (2000-2015)
    • 13.2 Immunochemistry Test Reagents Distribution Share (2007-2008)
    • 13.3 Immunochemistry Test Reagents, China, Company Share (2006-2007)
  • 14 Infectious Immunology Test Reagents In China
    • 14.1 Infectious Immunology Test Reagents Overall Revenue (2000-2015)
      • 14.1.1 Virology Revenue (2000-2015)
    • 14.2 Infectious Immunology Test Reagents Distribution Share (2007-2008)
    • 14.3 Infectious Immunology Test Reagents, China, Company Share (2006-2007)
  • 15 Instruments In China
    • 15.1 Instruments Overall Revenue (2000-2015)
    • 15.2 Instruments Distribution Share (2007-2008)
      • Instruments, China, Company Share (2006-2007)
      • Instruments, China, Company Share (2006-2007)
  • 16 Microbiology Test Reagents In China
    • 16.1 Microbiology Test Reagents Overall Revenue (2000-2015)
      • 16.1.1 Bacteriology Test Reagents Revenue (2000-2015)
    • 16.2 Microbiology Test Reagents Distribution Share (2007-2008)
    • 16.3 Microbiology Test Reagents, China, Company Share (2006-2007)
  • 17 Self Testing In China
    • 17.1 Self Testing Overall Revenue (2000-2015)
    • 17.2 Self Testing Distribution Share (2007-2008)
    • 17.3 Self Testing, China, Company Share (2006-2007)
  • 18 Overview of Key Companies in China In Vitro Diagnostics Market
    • 18.1 F. Hoffmann-La Roche Ltd
      • 18.1.1 Company Overview
      • 18.1.2 Value Chain Analysis
        • 18.1.2.1 Manufacturing
        • 18.1.2.2 Product Development
    • 18.2 Abbott Laboratories
      • 18.2.1 Company Overview
      • 18.2.2 Value Chain Analysis
        • 18.2.2.1 Manufacturing
        • 18.2.2.2 Product Development
        • 18.2.2.3 Sales and Marketing
    • 18.3 Beckman Coulter, Inc
      • 18.3.1 Company Overview
      • 18.3.2 Value Chain Analysis
        • 18.3.2.1 Manufacturing
        • 18.3.2.2 Product Development
        • 18.3.2.3 Sales and Marketing
      • 18.3.3 Beckman Coulter, Inc. Pipeline Products
        • 18.3.3.1 Beckman Coulter, Inc. Pipeline Products By Equipment Type
        • 18.3.3.2 Beckman Coulter, Inc. Pipeline Products By Development Stage
        • 18.3.3.3 Beckman Coulter, Inc. Pipeline Products By Therapy Area
        • 18.3.3.4 Beckman Coulter, Inc. Pipeline Products By News Summary
    • 18.4 Dade Behring Holdings, Inc
      • 18.4.1 Company Overview
    • 18.5 Ortho-Clinical Diagnostics Inc
      • 18.5.1 Company Overview
      • 18.5.2 Ortho-Clinical Diagnostics Inc. Pipeline Products
        • 18.5.2.1 Ortho-Clinical Diagnostics Inc. Pipeline Products By Equipment Type
        • 18.5.2.2 Ortho-Clinical Diagnostics Inc. Pipeline Products By Development Stage
        • 18.5.2.3 Ortho-Clinical Diagnostics Inc. Pipeline Products By Therapy Area
        • 18.5.2.4 Ortho-Clinical Diagnostics Inc. Pipeline Products By News Summary
    • 18.6 bioMerieux S.A
      • 18.6.1 Company Overview
      • 18.6.2 Value Chain Analysis
        • 18.6.2.1 Manufacturing
        • 18.6.2.2 Product Development
        • 18.6.2.3 Sales and Marketing
    • 18.7 Siemens Healthcare
      • 18.7.1 Company Overview
      • 18.7.2 Value Chain Analysis
        • 18.7.2.1 Manufacturing
        • 18.7.2.2 Product Development
        • 18.7.2.3 Sales and Marketing
    • 18.8 Gen-Probe Incorporated
      • 18.8.1 Company Overview
      • 18.8.2 Value Chain Analysis
        • 18.8.2.1 Manufacturing
        • 18.8.2.2 Product Development
        • 18.8.2.3 Sales and Marketing
      • 18.8.3 Gen-Probe Incorporated Pipeline Products
        • 18.8.3.1 Gen-Probe Incorporated Pipeline Products By Equipment Type
        • 18.8.3.2 Gen-Probe Incorporated Pipeline Products By Development Stage
        • 18.8.3.3 Gen-Probe Incorporated Pipeline Products By Therapy Area
        • 18.8.3.4 Gen-Probe Incorporated Pipeline Products By Clinical Trials
        • 18.8.3.5 Gen-Probe Incorporated Pipeline Products By News Summary
    • 18.9 Becton, Dickinson and
      • 18.9.1 Company Overview
      • 18.9.2 Value Chain Analysis
        • 18.9.2.1 Manufacturing
        • 18.9.2.2 Product Development
        • 18.9.2.3 Sales and Marketing
    • 18.10 OLYMPUS CORPORATION
      • 18.10.1 Company Overview
      • 18.10.2 Value Chain Analysis
        • 18.10.2.1 Manufacturing
        • 18.10.2.2 Product Development
        • 18.10.2.3 Sales and Marketing
      • 18.10.3 Olympus Medical Systems Corp. Pipeline Products
        • 18.10.3.1 Olympus Medical Systems Corp. Pipeline Products by Equipment Type
        • 18.10.3.2 Olympus Medical Systems Corp. Pipeline Products by Development Stage
        • 18.10.3.3 Olympus Medical Systems Corp. Pipeline Products by Therapy Area
        • 18.10.3.4 Olympus Medical Systems Corp. Pipeline Products by Clinical Trials
        • 18.10.3.5 Olympus Medical Systems Corp. Pipeline Products by News Summary
    • 18.11 Beijing Bio-Ekon Biotechnology Co., Ltd
      • 18.11.1 Company Overview
    • 18.12 Beijing Pason Pharmaceuticals Inc
      • 18.12.1 Company Overview
    • 18.13 Jingmei Biotech Co., Ltd
      • 18.13.1 Company Overview
    • 18.14 Mindray Medical International Limited
      • 18.14.1 Company Overview
    • 18.15 Shanghai Fosun Medical Technology Development Co., Ltd
      • 18.15.1 Company Overview
  • 19 Financial Deals Landscape
    • 19.1 Merger
      • 19.1.1 Pacgen Biopharmaceuticals Terminates Merger Agreement with Medigen Biotechnology
    • 19.2 Acquisition
      • 19.2.1 FUJIFILM Acquires Perseus Proteomics
    • 19.3 Partnerships
      • 19.3.1 Progentech Enters Into Partnership with China CDC
      • 19.3.2 Luminex Signs an Agreement with Mingyuan Medicare
  • 20 Recent Developments
    • 20.1 Strategy and Business Planning
      • 20.1.1 Jan 16, 2009: Mindray Plans to Launch Seven to Nine New Products In 2009
      • 20.1.2 Feb 28, 2008: Inverness Medical Plans To Close Unipath Facility
      • 20.1.3 Nov 05, 2007: Adaltis Signs Important Cooperation Agreement with CMDA
    • 20.2 Government and Public Interest
      • 20.2.1 Apr 01, 2009: Chinese Government and Foundation Announce Partnership to Fight TB
      • 20.2.2 Mar 18, 2009: MOH: New Rules to Govern High-Risk and Controversial Medical Technologies
    • 20.3 Product News
      • 20.3.1 Mar 25, 2009: China Medical Technologies Receives Receipt Of SFDA Quality Testing Certificate For Its SPR System
      • 20.3.2 Mar 06, 2009: QIAGEN Supports Cervical Cancer Screening For Underprivileged Chinese Women
      • 20.3.3 Feb 11, 2009: Zila Announces the Completion Of First Phase Global Rollout Of ViziLite Plus
      • 20.3.4 Jan 22, 2009: China Medical Technologies Receives SFDA Approval for Cervical Cancer FISH Probe and Prenatal FISH Probe
      • 20.3.5 Dec 01, 2008: Next-Generation Noninvasive Diagnostic Technology Shown to Accurately Detect Fetal down syndrome in First Trimester of Pregnancy
      • 20.3.6 Nov 12, 2008: China Medical Technologies Receives SFDA Approval For Breast Cancer HER-2 FISH Probe
      • 20.3.7 Jul 17, 2008: Mindray to Introduce BC-5380 Hematology Analyzer at AACC 2008
  • 21 Appendix
    • 21.1 Global Markets Direct Research Methodology
    • 21.2 Coverage
    • 21.3 Secondary Research
    • 21.4 Primary Research
    • 21.5 Models
    • 21.6 Forecasts
    • 21.7 Expert Panel Validation
    • 21.8 Currency Conversion
    • 21.9 Contact Us
    • 21.10 Disclaimer
  • 1 List of Tables
    • Table 1: Doctors by Specialty in China, 2003-2007
    • Table 2: Hospital Wards by Specialty in China, 2003 - 2007
    • Table 3: Healthcare Institutions in China, 2000-2006
    • Table 4: Personnel Employed in Healthcare Institutions in China, 2000-2006
    • Table 5: Healthcare Institutions, Hospital Beds and Employed Personnel by Region in China, 2006
    • Table 6: In Vitro Diagnostics Cross Country Comparison, Revenue ($ mn), 2000-2015
    • Table 7: In Vitro Diagnostics, China, Overall Revenue ($ mn), 2000-2015
    • Table 8: In Vitro Diagnostics, China, Cross-Category Analysis, 2000-2015
    • Table 9: In Vitro Diagnostics, China, Overall Revenue ($ mn), Historic, 2000-2008
    • Table 10: In Vitro Diagnostics, China, Overall Revenue ($ mn), Forecast, 2008-2015
    • Table 11: In Vitro Diagnostics, China, Company Share by Revenue ($ mn), 2006-2007
    • Table 12: Blood Test Reagents, China, Revenue ($ mn) by Segment, Historic, 2000-2008
    • Table 13: Blood Test Reagents, China, Revenue ($ mn) by Segment, Forecast, 2008-2015
    • Table 14: Haematology Test Reagents, China, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
    • Table 15: Haematology Test Reagents, China, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
    • Table 16: Hemostasis Test Reagents, China, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
    • Table 17: Hemostasis Test Reagents, China, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
    • Table 18: Blood Test Reagents, China, Distribution Share by Revenue ($mn), 2007-2008
    • Table 19: Blood Test Reagents, China, Company Share by Revenue ($ mn), 2006-2007
    • Table 20: Clinical Chemistry Test Reagents, China, Revenue ($ mn) by Segment, Historic, 2000-2008
    • Table 21: Clinical Chemistry Test Reagents, China, Revenue ($ mn) by Segment, Forecast, 2008-2015
    • Table 22: Clinical Chemistry Test Reagents, China, Distribution Share by Revenue ($mn), 2007-2008
    • Table 23: Clinical Chemistry Test Reagents, China, Company Share by Revenue ($ mn), 2006-2007
    • Table 24: Genetic Test Reagents, China, Revenue ($ mn), Historic, 2000-2008
    • Table 25: Genetic Test Reagents, China, Revenue ($ mn), Forecast, 2008-2015
    • Table 26: Genetic Test Reagents, China, Distribution Share by Revenue ($mn), 2007-2008
    • Table 27: Genetic Test Reagents, China, Company Share by Revenue ($ mn), 2006-2007
    • Table 28: Immunochemistry Test Reagents, China, Revenue ($ mn) by Segment, Historic, 2000-2008
    • Table 29: Immunochemistry Test Reagents, China, Revenue ($ mn) by Segment, Forecast, 2008-2015
    • Table 30: Disease Specific Markers, China, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
    • Table 31: Disease Specific Markers, China, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
    • Table 32: Disease Specific Test Reagents, China, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
    • Table 33: Disease Specific Test Reagents, China, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
    • Table 34: Drug Related Testing Reagents, China, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
    • Table 35: Drug Related Testing Reagents, China, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
    • Table 36: Hormone Related Testing Reagents, China, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
    • Table 37: Hormone Related Testing Reagents, China, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
    • Table 38: Immunochemistry Test Reagents, China, Distribution Share by Revenue ($mn), 2007-2008
    • Table 39: Immunochemistry Test Reagents, China, Company Share by Revenue ($ mn), 2006-2007
    • Table 40: Infectious Immunology Test Reagents, China, Revenue ($ mn) by Segment, Historic, 2000-2008
    • Table 41: Infectious Immunology Test Reagents, China, Revenue ($ mn) by Segment, Forecast, 2008-2015
    • Table 42: Virology, China, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
    • Table 43: Virology, China, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
    • Table 44: Infectious Immunology Test Reagents, China, Distribution Share by Revenue ($mn), 2007-2008
    • Table 45: Infectious Immunology Test Reagents, China, Company Share by Revenue ($ mn), 2006-2007
    • Table 46: Instruments, China, Revenue ($ mn), Historic, 2000-2008
    • Table 47: Instruments, China, Revenue ($ mn), Forecast, 2008-2015
    • Table 48: Instruments, China, Distribution Share by Revenue ($mn), 2007-2008
    • Table 49: Instruments, China, Company Share by Revenue ($ mn), 2006-2007
    • Table 50: Microbiology Test Reagents, China, Revenue ($ mn) by Segment, Historic, 2000-2008
    • Table 51: Microbiology Test Reagents, China, Revenue ($ mn) by Segment, Forecast, 2008-2015
    • Table 52: Bacteriology Test Reagents, China, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
    • Table 53: Bacteriology Test Reagents, China, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
    • Table 54: Microbiology Test Reagents, China, Distribution Share by Revenue ($mn), 2007-2008
    • Table 55: Microbiology Test Reagents, China, Company Share by Revenue ($ mn), 2006-2007
    • Table 56: Self Testing, China, Revenue ($ mn), Historic, 2000-2008
    • Table 57: Self Testing, China, Revenue ($ mn), Forecast, 2008-2015
    • Table 58: Self Testing, China, Distribution Share by Revenue ($mn), 2007-2008
    • Table 59: Self Testing, China, Company Share by Revenue ($ mn), 2006-2007
    • Table 60: Beckman Coulter, Inc. Pipeline Products by Equipment Type
    • Table 61: Beckman Coulter, Inc. Pipeline Products By Development Stage
    • Table 62: Beckman Coulter, Inc. Pipeline Products By Therapy Area
    • Table 63: Beckman Coulter, Inc. Pipeline Products By News Summary
    • Table 64: Ortho-Clinical Diagnostics Inc. Pipeline Products by Equipment Type
    • Table 65: Ortho-Clinical Diagnostics Inc. Pipeline Products By Development Stage
    • Table 66: Ortho-Clinical Diagnostics Inc. Pipeline Products By Therapy Area
    • Table 67: Ortho-Clinical Diagnostics Inc. Pipeline Products By News Summary
    • Table 68: Gen-Probe Incorporated Pipeline Products by Equipment Type
    • Table 69: Gen-Probe Incorporated Pipeline Products By Development Stage
    • Table 70: Gen-Probe Incorporated Pipeline Products By Therapy Area
    • Table 71: Gen-Probe Incorporated Pipeline Products By Clinical Trials
    • Table 72: Gen-Probe Incorporated Pipeline Products By News Summary
    • Table 73: Olympus Medical Systems Corp. Pipeline Products by Equipment Type
    • Table 74: Olympus Medical Systems Corp. Pipeline Products by Development Stage
    • Table 75: Olympus Medical Systems Corp. Pipeline Products by Therapy Area
    • Table 76: Olympus Medical Systems Corp. Pipeline Products by Clinical Trials
    • Table 77: Olympus Medical Systems Corp. Pipeline Products by News Summary
    • Table 78: Pacgen Biopharmaceuticals Terminates Merger Agreement With Medigen Biotechnology
    • Table 79: FUJIFILM Acquires Perseus Proteomics
    • Table 80: Progentech Enters Into Partnership With China CDC
    • Table 81: Luminex Signs An Agreement With Mingyuan Medicare
    • Table 82: USD to Local Currency, Average Exchange Rate 2008
  • 1.2 List of Figures
    • Figure 1: Total Healthcare Expenditure in China, 2000 - 2005
    • Figure 2: Medical Equipment Registration Process in China, 2007
    • Figure 3: CCC Mark Certification Process in China, 2007
    • Figure 4: In Vitro Diagnostics Cross Country Comparison, Revenue ($ mn), 2000-2015
    • Figure 5: In Vitro Diagnostics, China, Overall Revenue ($ mn), 2000-2015
    • Figure 6: In Vitro Diagnostics, China, Cross-Category Analysis, 2000-2015
    • Figure 7: In Vitro Diagnostics, China, Overall Revenue ($ mn), Historic, 2000-2008
    • Figure 8: In Vitro Diagnostics, China, Overall Revenue ($ mn), Forecast, 2008-2015
    • Figure 9: In Vitro Diagnostics, China, Company Share (%), 2007
    • Figure 10: Blood Test Reagents, China, Revenue ($ mn) by Segment, Historic, 2000-2008
    • Figure 11: Blood Test Reagents, China, Revenue ($ mn) by Segment, Forecast, 2008-2015
    • Figure 12: Haematology Test Reagents, China, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
    • Figure 13: Haematology Test Reagents, China, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
    • Figure 14: Hemostasis Test Reagents, China, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
    • Figure 15: Hemostasis Test Reagents, China, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
    • Figure 16: Blood Test Reagents, China, Company Share (%), 2007
    • Figure 17: Clinical Chemistry Test Reagents, China, Revenue ($ mn) by Segment, Historic, 2000-2008
    • Figure 18: Clinical Chemistry Test Reagents, China, Revenue ($ mn) by Segment, Forecast, 2008-2015
    • Figure 19: Clinical Chemistry Test Reagents, China, Company Share (%), 2007
    • Figure 20: Genetic Test Reagents, China, Revenue ($ mn), Historic, 2000-2008
    • Figure 21: Genetic Test Reagents, China, Revenue ($ mn), Forecast, 2008-2015
    • Figure 22: Genetic Test Reagents, China, Company Share (%), 2007
    • Figure 23: Immunochemistry Test Reagents, China, Revenue ($ mn) by Segment, Historic, 2000-2008
    • Figure 24: Immunochemistry Test Reagents, China, Revenue ($ mn) by Segment, Forecast, 2008-2015
    • Figure 25: Disease Specific Markers, China, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
    • Figure 26: Disease Specific Markers, China, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
    • Figure 27: Disease Specific Test Reagents, China, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
    • Figure 28: Disease Specific Test Reagents, China, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
    • Figure 29: Drug Related Testing Reagents, China, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
    • Figure 30: Drug Related Testing Reagents, China, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
    • Figure 31: Hormone Related Testing Reagents, China, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
    • Figure 32: Hormone Related Testing Reagents, China, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
    • Figure 33: Immunochemistry Test Reagents, China, Company Share (%), 2007
    • Figure 34: Infectious Immunology Test Reagents, China, Revenue ($ mn) by Segment, Historic, 2000-2008
    • Figure 35: Infectious Immunology Test Reagents, China, Revenue ($ mn) by Segment, Forecast, 2008-2015
    • Figure 36: Virology, China, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
    • Figure 37: Virology, China, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
    • Figure 38: Infectious Immunology Test Reagents, China, Company Share (%), 2007
    • Figure 39: Instruments, China, Revenue ($ mn), Historic, 2000-2008
    • Figure 40: Instruments, China, Revenue ($ mn), Forecast, 2008-2015
    • Figure 41: Instruments, China, Company Share (%), 2007
    • Figure 42: Microbiology Test Reagents, China, Revenue ($ mn) by Segment, Historic, 2000-2008
    • Figure 43: Microbiology Test Reagents, China, Revenue ($ mn) by Segment, Forecast, 2008-2015
    • Figure 44: Bacteriology Test Reagents, China, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
    • Figure 45: Bacteriology Test Reagents, China, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
    • Figure 46: Microbiology Test Reagents, China, Company Share (%), 2007
    • Figure 47: Self Testing, China, Revenue ($ mn), Historic, 2000-2008
    • Figure 48: Self Testing, China, Revenue ($ mn), Forecast, 2008-2015
    • Figure 49: Self Testing, China, Company Share (%), 2007
    • Figure 50: F. Hoffmann-La Roche Ltd Value Chain Analysis
    • Figure 51: Abbott Laboratories Value Chain Analysis
    • Figure 52: Beckman Coulter, Inc. Value Chain Analysis
    • Figure 53: Biomerieux Sa Value Chain Analysis
    • Figure 54: Siemens Medical Solutions Value Chain Analysis
    • Figure 55: Gen-Probe Incorporated Value Chain Analysis
    • Figure 56: Becton, Dickinson and Company Value Chain Analysis
    • Figure 57: Olympus Medical Systems Corp. Value Chain Analysis
    • Figure 58: Global Markets Direct Methodology